Europe Transcatheter Heart Valves Market (2022-2033)

Growing prevalence of heart valve degeneration

Europe is facing a steadily rising burden of valvular heart diseases, particularly among older adults. Degenerative conditions, such as aortic stenosis and mitral regurgitation, are common in aging populations, creating sustained demand for minimally invasive treatment options such as transcatheter heart valves (THVs). As life expectancy rises across the continent, hospitals are seeing a growing number of patients who require timely interventions to prevent heart failure and other serious complications.

The high prevalence of valvular disorders has prompted healthcare systems to focus on early diagnosis and intervention. Routine echocardiography and advanced imaging are uncovering previously undiagnosed cases, driving the need for transcatheter solutions that can be delivered with reduced procedural risk. This shift aligns with broader trends in European cardiology toward precision medicine and patient-centered care, where clinicians aim to optimize outcomes while minimizing hospital stays.

Clinical guidelines and consensus statements from European cardiology societies emphasize minimally invasive approaches for high- and intermediate-risk patients. This endorsement has encouraged the adoption of THVs across major cardiac centers, reinforcing their role as a standard treatment option. Hospitals are thus aligning their structural heart programs with evidence-based protocols, ensuring that the infrastructure and training required for transcatheter procedures are widely available.

Broader adoption of mitral & tricuspid transcatheter therapy

While aortic valve interventions remain the backbone of transcatheter procedures in Europe, mitral and tricuspid valve applications are emerging as important growth areas. Advancements in transcatheter mitral valve repair and replacement have allowed clinicians to treat patients who were previously considered inoperable due to age or comorbidities. These therapies are becoming integrated into clinical practice, supported by a growing body of evidence demonstrating safety and effectiveness.

Tricuspid valve interventions, once rare, are also gaining momentum in specialized European heart centers. Clinicians are leveraging new transcatheter technologies to manage right-sided valvular disease, particularly in patients with heart failure or pulmonary hypertension. The availability of dedicated devices and improvements in procedural techniques are expanding the range of patients who can benefit from minimally invasive solutions.

Innovations in device design and delivery systems are enhancing procedural efficiency and outcomes. Hybrid approaches, such as valve-in-valve techniques and combination repair-replacement strategies, are becoming more widely adopted, allowing heart teams to tailor interventions to individual patient anatomy and disease complexity. As European hospitals continue to build expertise in structural heart disease, the adoption of mitral and tricuspid transcatheter therapies is expected to accelerate, complementing established aortic programs.

The "Europe Transcatheter Heart Valves Market Size and Forecast (2022–2033)" report provides a detailed analysis of the market covering below areas:

• Europe Transcatheter Heart Valves market size and forecast at regional and country levels for key market segments covered under the scope
• Europe Transcatheter Heart Valves market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• Europe Transcatheter Heart Valves market analysis covering key market trends, regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the Europe Transcatheter Heart Valves market
• Detailed company profiles, including SWOT analysis

The geographical scope of the Europe Transcatheter Heart Valves market report is divided into: Germany, Italy, France, the UK, Spain, Belgium, the Netherlands, Luxembourg, Norway, Finland, Denmark, Sweden, Austria, Switzerland, Russia, Romania, Greece, the Czech Republic, Portugal, Ukraine, Poland, Slovakia, and Bulgaria. Germany held the largest share in 2024.

Germany represents the dominant country in the Europe transcatheter heart valves market, driven by its advanced healthcare infrastructure, strong clinical expertise, and long-standing leadership in cardiovascular medicine. The country is recognized for its early adoption of innovative medical technologies and its strong emphasis on minimally invasive treatment modalities, particularly in the field of interventional cardiology. German hospitals are equipped with state-of-the-art catheterization laboratories and hybrid operating rooms, enabling efficient and safe performance of transcatheter heart valve procedures. A well-structured referral system and the presence of multidisciplinary heart teams support accurate patient selection and consistent procedural outcomes, reinforcing physician and patient confidence in transcatheter therapies.

Germany's healthcare reimbursement environment plays a crucial role in facilitating access to these procedures, allowing hospitals to integrate transcatheter valve interventions into routine clinical practice. Furthermore, the country's active participation in clinical research, registries, and post-market surveillance initiatives contributes to continuous evaluation and optimization of treatment protocols. At the same time, the German market is influenced by increasing focus on long-term clinical outcomes, device durability, and cost-effectiveness, particularly as transcatheter therapies are considered for broader patient populations. Despite these considerations, Germany continues to set clinical and procedural benchmarks for transcatheter heart valve adoption across Europe.

• The report includes qualitative and quantitative data in the Europe Transcatheter Heart Valves market across valve type, application, end user, and geography.
• The report starts with the key takeaways (chapter 2), highlighting the key trends and outlook of the Europe Transcatheter Heart Valves market.
• Chapter 3 includes the research methodology of the study.
• Chapter 4 further includes ecosystem analysis.
• Chapter 5 highlights the major industry dynamics in the Europe Transcatheter Heart Valves market, including factors that are driving the market, prevailing deterrents, potential opportunities, as well as future trends. Impact analysis of these drivers and restraints is also covered in this section.
• Chapter 6 discusses the Europe Transcatheter Heart Valves market scenario, in terms of historical market revenues, and forecast till the year 2033.
• Chapters 7 to 10 cover Europe Transcatheter Heart Valves market segments by valve type, application, end user, and geography across Germany, Italy, France, the UK, Spain, Belgium, the Netherlands, Luxembourg, Norway, Finland, Denmark, Sweden, Austria, Switzerland, Russia, Romania, Greece, the Czech Republic, Portugal, Ukraine, Poland, Slovakia, and Bulgaria. They cover the market revenue, forecast, and factors driving the market.
• Chapter 11 describes the competitive analysis along with the heat map analysis for the key players operating in the market.
• Chapter 12 describes the industry landscape analysis. It provides detailed descriptions of business activities such as market initiatives, new developments, mergers, and joint ventures globally, along with a competitive landscape.
• Chapter 13 provides detailed profiles of the major companies operating in the Europe Transcatheter Heart Valves market. Companies have been profiled on the basis of their key facts, business descriptions, products, financial overview, SWOT analysis, and key developments.
• Chapter 14, i.e., the appendix, is inclusive of a brief overview of the company, list of abbreviations, and disclaimer.

The Europe Transcatheter Heart Valves market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the Europe transcatheter heart valves market are:

• In August 2025, Abbott announced that its Navitor TAVI System received a CE mark for an expanded indication to treat symptomatic severe aortic stenosis in patients at low and intermediate surgical risk, broadening the eligible patient population across Europe.
• In January 2025, Medtronic announced that its Harmony Transcatheter Pulmonary Valve (TPV) System received the CE mark in the European Union, enabling minimally invasive pulmonary valve replacement for patients with native or surgically repaired right ventricular outflow tract issues.